BioMarin PharmaceuticalsBMRN
Market Cap: $16B
About: BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Employees: 3,401
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1% more funds holding
Funds holding: 539 [Q1] → 546 (+7) [Q2]
9% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 82
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 189
0.44% less ownership
Funds ownership: 97.47% [Q1] → 97.02% (-0.44%) [Q2]
8% less call options, than puts
Call options by funds: $153M | Put options by funds: $166M
6% less capital invested
Capital invested by funds: $16.1B [Q1] → $15.2B (-$897M) [Q2]
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target | 43%upside $120 | Overweight Maintained | 5 Sept 2024 |
RBC Capital Luca Issi 33% 1-year accuracy 16 / 48 met price target | 19%upside $100 | Sector Perform Reiterated | 5 Sept 2024 |
Scotiabank George Farmer 40% 1-year accuracy 6 / 15 met price target | 13%upside $95 | Sector Perform Maintained | 5 Sept 2024 |
Piper Sandler Christopher Raymond 43% 1-year accuracy 12 / 28 met price target | 45%upside $122 | Overweight Maintained | 5 Sept 2024 |
Truist Securities Joon Lee 62% 1-year accuracy 28 / 45 met price target | 40%upside $118 | Buy Maintained | 5 Sept 2024 |
Financial journalist opinion
Based on 17 articles about BMRN published over the past 30 days